



ELSEVIER

Read and Publish Agreements

Key features



Definitions for RAP



Terminology	Definition
Submitting corresponding author	<p data-bbox="517 288 1812 361">Submitting corresponding author is the author who submits the article to Elsevier and stays in contact with Elsevier in the end-to-end publishing journey</p> <p data-bbox="517 405 1676 478">This is the author who makes the publishing choice on behalf of the author group. Every article has only one submitting corresponding author</p>
Acceptance Date	<p data-bbox="517 503 1375 536">This is the date the journal accepts the article for publication</p>
Elsevier OA Platform	<p data-bbox="517 568 1692 642">Elsevier OA Platform (EOAP) is a user-friendly interface where we present the institutional administrators with the open access articles eligible for the agreement.</p> <p data-bbox="517 685 1711 758">Administrators at the institution usually validate the eligibility of the author for an OA agreement. We are piloting 'no validation' to address customer need.</p> <p data-bbox="517 802 1823 911">Agreement partners can keep track of the performance of their agreement using EOAP's reporting capabilities. Internal users can also access this function to monitor progress of the agreements they are involved with.</p>

Eligibility criteria

Eligibility component	Description
Acceptance date	The acceptance date of the article should fall within the agreement term dates for your institution.
Author affiliation	<p>The submitting corresponding author must be affiliated with a participating institution in the agreement.</p> <p>We rely on submitting corresponding authors declaring their affiliation as part of submission & post acceptance journeys. This is why validation by the institutional admins on the author eligibility is important.</p>
Journal title	The article must be submitted to and accepted in a participating journal. For most agreements, this will be the core hybrid journals to which the customer have access through their SD contract.
Article type	The article type must be eligible. These are the OA article types that have peer reviewed content (FLAs, REVs, SCOs etc)



ELSEVIER

Publishing Options

The author workflow



Publishing options at submission (Editorial Manager)

As part of the submission journey, once the author uploads the manuscript files, the corresponding author provides the affiliation details

Edit Author Details

Mr. [Corresponding Author] [First Author] [You]

[Insert Special Characters](#)

Your Given/First Name*

Secondary Given/First Name ⓘ

Middle Name

Your Family/Last Name*

Secondary Family/Last Name ⓘ

Academic Degree(s)

Your E-mail Address*

ORCID [Fetch/Register](#)

[What is ORCID?](#)

Institution*

Country or Region

Contributor Roles*

- Waseda University School of Advanced Science and Engineering Department of Applied Chemistry**
Shinjuku-Ku, JP
- Waseda University Center for Advanced Biomedical Sciences**
Shinjuku-Ku, JP
- Waseda University Faculty of Political Science and Economics**
Shinjuku-Ku, JP

[+ Add Another Author](#)

[Next](#)

[Back](#) [Save & Submit Later](#) [Build PDF for Approval](#)

The system presents information about the publishing options and informs the author that the choice they make at submission is an indication



Elsevier Publishing Options

Please indicate your Publishing Options


This is a hybrid journal. The journal publishes both subscription and OA articles. We will present your personalized Publishing Options based on the Institution and Funding details you have given us. Please note that at this stage in your submission, you are only indicating your preference. We will ask you to make a final choice after the journal has accepted your manuscript.



The system presents personalized publishing options for the relevant agreement as the author has met all the eligibility criteria

Test ⌵

Tell us how you want your work to be made available



Agreement between JUSTICE and Elsevier
Waseda University is part of this agreement. As a corresponding author affiliated with Waseda University, you can publish open access at no cost. You must be accepted for publication by 31 December 2027.
[Read more about the agreement between JUSTICE and Elsevier](#)

Important information before you complete your submission


Availability and sharing of your article
If accepted for publication, your article will be made immediately available to everyone. It can be shared and reused in the ways described by the [Creative Commons end user license](#) you select.

Institutional and funder agreements
If accepted, any fees covered under agreements are subject to institution or funder approval, and fund availability. You may wish to check before proceeding.

Payment of open access fees
Open access fees only apply if accepted. Payment is your responsibility. If we invoice your institution and don't receive payment, or if fees covered under agreements are not approved, we will reissue the invoice to you. Or, if the journal allows it, you can choose to publish subscription at no cost to you.

Rights and access
If accepted, you must complete a publishing agreement to ensure we publish your article in the way you want. If the publishing agreement is not completed, we will apply a default Creative Commons end user license. Or, if the journal allows it, we will publish it as a subscription article.
If you don't agree to the above and to the full [Elsevier terms and conditions of purchase for open access services](#) you should not proceed with your submission.


To pay on acceptance

 Only applicable if article accepted


Price


⊖ APC **JPY 508,240.00**

Institutional Agreement Discount

 **-508,240.00**

To pay (on validation) **0.00**





Publishing options after acceptance

The corresponding author receives an email post acceptance with a unique link to complete the author journey and choose publishing options

The author clicks on Complete the Rights and Access information form

In a Hybrid journal, the author needs to complete the journey to be able to publish OA

In case the author doesn't complete the post acceptance journey, the article will be published subscription

Thank you for your contribution please use a Microsoft permanent email



Corresponding author	[REDACTED]
E-mail address	[REDACTED]
Journal	International Journal of Pharmaceutics
Article number	121624
Our reference	IJP_121624
PII	S0378-5173(22)00179-X

Welcome [REDACTED]

To help us finalize the publication of your article please complete the publishing form(s) below.

Note: you will receive a confirmation e-mail after completing each form.

 Information you may need to provide to complete the forms



Rights and Access

[Complete the rights and access form >](#)

Help and Support

[How you can share your article](#)



[Author rights information](#)

[A guide to publishing Open Access](#)

Rights and Access

1

Corresponding
Author

2

Co-Author

3

Research
Funders

4

Publishing
Options

5

Review Order

6

Confirmation

The corresponding author selects his/her affiliation details which we use to identify the authors and match them to the relevant agreement

Please note that when the author has already provided this information at submission; it is prepopulated

Corresponding author
E-mail address
Journal
Article number
Our reference
PII

Corresponding Author's Organization ⓘ

Please enter the corresponding author's organization. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

Hint: start your search using your main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find your specific department, then selecting your main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

Organization name*

Tulane University|

Tulane University

New Orleans, US

Tulane University of Louisiana

New Orleans, US

Tulane University School of Medicine

New Orleans, US

Tulane University Hospital and Clinic

New Orleans, US

Tulane Medical Center

New Orleans, US

Tulane Medical Center Downtown

New Orleans, US

Tulane University Health Sciences Center

Save and Continue >

- Based on the affiliation details, the author sees the Publishing Options. The Gold OA option is followed by the Subscription option, and we inform the author that the agreement covers the APC.
- If the librarian/admin at the institution rejects the author request in the Elsevier Platform, we also make it clear that the authors will receive a full price invoice.
- The author selects Gold OA.

Gold Open Access

Publish as an Open Access article

Make my published article available to everyone.

As a corresponding author affiliated with the **Tulane University**, upon validation, [the agreement between Tulane University and Elsevier](#) will cover the APC.

I and others can share and reuse my article in the ways described by the user license I select.

Article Publishing Charge (APC)

Price

USD 3,150.00

Institutional Agreement Discount



- 3,150.00

To pay (on validation)



0.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 3,150.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[Tulane University and Elsevier Agreement](#)

Subscription

Publish as a subscription article


I will publish my article subscription, making my final published article immediately available to journal subscribers, and to other groups as part of [Elsevier's programs](#).

I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 13 July 2026. I have additional article sharing rights outlined [here](#).

Previous

Save and Continue >

Rights and Access



- The system presents the author with the CC license options.
- By default, we offer 3 standard licenses.
- The author selects the CC BY option.

Select your user license

Please select your license. If you need to comply with a mandated license and the mandated license is not listed below, please visit our [Support Hub](#) for additional help.

- CC BY 4.0
A license to permit readers to share and adapt your article for any purpose, even commercially.
[Read more about CC BY 4.0](#)
- CC BY-NC-ND 4.0
A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.
[Read more about CC BY-NC-ND 4.0](#)
- CC BY-NC 4.0
A license for readers to share and adapt your article for non-commercial purposes. Permission from Elsevier is required for commercial use of the article.
[Read more about CC BY-NC 4.0](#)

[Previous](#)[Save and Continue >](#)

[Redacted text] 

Elsevier Ltd

Select Your Status

- I am the sole author of the manuscript 
- I am one author signing on behalf of all co-authors of the manuscript and I am duly authorized to do so by all co-authors of the manuscript 
 - Please indicate which of the below applies to you:
 - We are all US Government employees and the Article is public domain and therefore the 'License of publishing rights' clause does not apply
 - I am a US Government employee but some of my co-authors are not
 - I am not a US Government employee but some of my co-authors are
 - The work was performed by contractors of the US Government under contract number:


Contract Number* _____
 - All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted
 - Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted
 - None of the above
- I am signing as a duly authorized representative and on behalf of my employer 

Signed on Behalf of Corresponding Author

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.

- I am signing on behalf of the corresponding author
 - Name, job title and company (if employer representative)* _____
 - E-mail address* _____

The author selects the options that drives the appropriate copyright statement on the article



[Redacted area] ▼

Elsevier Inc.

Your Status

- I am one author signing on behalf of all co-authors of the manuscript and I am duly authorized to do so by all co-authors of the manuscript

License of Publishing Rights

I hereby grant to Elsevier Inc. an irrevocable non-exclusive license to publish, distribute and otherwise use all or any part of the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in all forms and media (whether now known or later developed) in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication.

I acknowledge the importance of the integrity, authenticity and permanence of the scholarly record and agree that the version of the Article that appears or will appear in the journal and embodies all value-adding publisher activities (including peer review co-ordination, copy-editing, formatting, (if relevant) pagination, and online enrichment) shall be the definitive final record of published research ("the Published Journal Article").

I further acknowledge and agree that nothing in this Agreement shall be deemed to permit redundant/duplicate publication of the Article in violation of publishing ethics principles, as further described below.

Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier Inc. shall have a perpetual worldwide, non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials in all forms and media (whether now known or later developed), and to permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.

The system presents the author with the Journal License Publishing Agreement

The author agrees to the Journal License Publishing Agreement

Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses which conflict with the terms of this License Agreement.
- If I and/or any of my co-authors reside in Russia, Belarus, Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/patient-consent> for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier Inc. ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <http://www.elsevier.com/copyright>.


I have read and agree to the terms of the License Agreement.

13 August 2024

T-copyright license-v6/2024

Previous

Accept Agreement >



Once the author clicks on 'Finish':

- Corresponding author and co-authors receive a copy of the summary via email.
- The article becomes OA on ScienceDirect within 24 hours.
- The Librarian/admin at the institution will receive a notification for validation within 48 hours and then has 3 weeks to validate the request.
- If the Librarian/admin approves the request, the author will receive the full APC coverage.
- If the Librarian/admin rejects the request, the author will receive the full price invoice.

Review Order


Research Funders	Milliman Inc Grant numbers: GT123
Publishing Option	Gold Open Access
User License	CC BY 4.0
Publishing Agreement	<ul style="list-style-type: none">• I am one author signing on behalf of all co-authors of the manuscript and I am duly authorized to do so by all co-authors of the manuscript <p>I may share my final published article widely in accordance with the user License that I have selected. Further details on Elsevier Sharing Policy here.</p>


13 August 2024

[Previous](#) [Finish >](#)

Total payment due

Price (excluding taxes)
USD **3,150.00**

Institutional Agreement Discount
 - 3,150.00

To pay (on validation)
 **0.00**

If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 3,150.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[Tulane University and Elsevier Agreement](#)